创新药板块涨幅靠前，睿智医药20cm涨停，海南海药、联化科技、哈三联、华森制药等多股10cm涨停。消息面上，5 月29日，国家药品监督管理局批准了11款创新药物上市，相关研发成果涉及多个新药研发技术领域，覆盖了肿瘤、自 身免疫性疾病、代谢等多个治疗领域。其中，多款药品为相关领域"国内首款"或"国产首款"。 | 代码 | 名称 | 涨幅量 | 涨跌 | 现价 | | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | +19.98% | +1.71 | 10.27 | | 688131 | 皓元医药 | +15.26% | +5.84 | 44.10 | | 300204 | 計泰神 | +15.02% | +3.46 | 26.50 | | 430047 | 诺思兰德 | +14.87% | +2.71 | 20.94 | | 688799 | 华纳药厂 | +12.94% | +5.31 | 46.36 | | 688488 | 艾迪药业 | +11.96% | +1.48 | 13.85 | | 000266 | 海南海药 | +10.07% | +0.56 | ...

5月30日，截至收盘，沪指跌0.47%，深成指跌0.85%，创业板指跌0.96%。 | 全A | 涨 1116 | 平 134 | 跌 4158 A股成 | | --- | --- | --- | --- | | 序号 代码 | 名称 | 现价 | 涨跌 涨跌幅 | | 1 | 000001 上证指数 | 3347.49 c | -15.96 -0.47% | | 2 | 399001 深证成指 | 10040.63c | -86.58 -0.85% | | 3 | 899050 北证50 | 1408.69 c | -7.16 -0.51% | | 4 | 881001 万得全A | 5074.29 c | -42.21 -0.83% | | 5 | 000688 889000 | 977.03 c | -9.28 -0.94% | | 6 | 399006 创业板指 | 1993.19 c | -19.36 -0.96% | | 7 | 000300 沪深300 | 3840.23 c | -18.47 -0.48% | 沪深两市全天成交额1.14万亿，个股跌多涨少，全市场超4100只个股下跌。 盘面上看 ...

Market Overview - The Asia-Pacific markets collectively declined, with the Nikkei 225 and the Korea Composite Index dropping nearly 1%, and the Hang Seng Index falling by 1.5% during intraday trading [1] - The A-share market also saw all three major indices decline, with several high-priced stocks like Wangzi New Materials and Yong'an Pharmaceutical hitting the daily limit down [2] High-priced Stocks Plummet - High-priced stocks experienced significant drops, with Wangzi New Materials hitting the daily limit down at a price of 19.67 CNY per share, reflecting a decline of 9.98% [4][5] - Yong'an Pharmaceutical also faced a daily limit down, citing a significant deviation from its fundamentals and warning of high speculation risks [7] - Other high-priced stocks such as Shangwa Co., Guofang Group, and others also reported substantial declines [13] Innovation Drug Sector Strengthens - The pharmaceutical sector, particularly innovative drugs, saw a strong performance, with companies like Ruizhi Pharmaceutical and Nuo Si Lan De rising over 15% [15] - The National Medical Products Administration recently approved 11 new drug listings, covering various therapeutic areas, which has contributed to the positive sentiment in the sector [19] - Analysts believe that the pharmaceutical sector is supported by four key factors: ongoing demand for healthcare, increasing global competitiveness of domestic innovative drugs, signs of profit reversal, and low valuations in the innovative drug sector [20][21] Livestock Sector Leads Gains - The livestock sector led the market gains, with pig and chicken farming concepts showing the highest increases, including stocks like Juxing Agriculture and Xiangjia Co. hitting the daily limit up [23] - Recent legislative efforts in Shanghai and Sichuan aim to support the development of the livestock industry, which may further bolster the sector [26]

Market Overview - The A-share market experienced an overall decline on May 30, with most major indices falling, although the declines were generally modest [2][6] - The Hong Kong market also saw a drop, with the Hang Seng Index falling over 1% [6] Innovation Drug Sector - The innovation drug concept surged, with the sector showing an overall increase of approximately 3%, leading to a wave of stocks hitting the daily limit up [2] - Notable stocks in the innovation drug sector included Ruizhi Pharmaceutical, which hit a limit up of 20cm, and Warner Pharmaceuticals, both seeing significant gains [2][3] - The sector's performance is supported by recent research indicating that the number of Chinese innovative drugs selected for the 2025 ASCO summary has reached a new high, reflecting a leap in R&D competitiveness and increasing international influence [4] Specific Company Performances - In the Hong Kong market, CSPC Pharmaceutical Group saw its stock price surge by over 12% following the announcement of potential licensing and cooperation deals, with total potential payments from these deals estimated to reach around $5 billion [6] - Li Auto reported a total vehicle delivery of 92,864 units in Q1 2025, marking a year-on-year increase of 15.5%, with total revenue reaching RMB 25.9 billion, a slight increase from the previous year [7] - Li Auto's net profit for Q1 2025 was RMB 646.6 million, up 9.4% year-on-year, although it represented a significant decrease from the previous quarter [8]

A股市场今天（5月30日）上午整体走低，主要指数多数下跌，创新药概念掀起涨停潮，成为上午A股市场主要亮点之一。 港股市场方面，恒生指数盘中跌幅超过1%。受到利好消息刺激，石药集团上午盘中一度暴涨逾12%。理想汽车-W上午股价亦大涨。 A股今天上午整体走低 创新药概念掀起涨停潮 A股市场今天上午整体走低，主要指数多数下跌，不过跌幅普遍也不大。 行业板块和赛道方面，若按照申万一级行业划分，电子、汽车、机械设备等板块领跌，计算机、电力设备、通信等板块跌幅居前。 农林牧渔、医药生物等板块逆市抗跌。 概念板块方面，创新药概念大涨，板块整体涨幅一度在3%左右。板块内个股则掀起涨停潮，睿智医药、华纳药厂盘中"20cm"涨停，另有10多股盘中涨停或涨幅超 过10%。 | | 创新药 | | EQG | | --- | --- | --- | --- | | | 1021.75 +25.02 +2.51% | | | | 关联基金 成分股 | 讨论 | F10 | | | 诺思兰德 | 22.39 +22.82% 61.41亿 | | | | 430047 | | | | | 睿智医药 | 10.27 | +19.98% | ...

今天上午，医药股集体上涨，睿智医药、舒泰神、华纳药厂等个股大涨，恒瑞医药、百济神州、百利天 恒等市值超千亿元的龙头股上涨。 跌幅榜前列，几乎都是近期的高位股。 王子新材（002735）、尚纬股份（603333）等多只个股跌停。 具有防御属性的银行和养殖业板块上午走强。其中，银行板块内个股全部上涨，杭州银行、成都银行盘 中股价创历史新高。养殖业板块中，巨星农牧、神农集团等个股大涨。 截至上午收盘，上证指数下跌0.31%，深证成指下跌0.75%，创业板指下跌0.88%。 | 上证指数 | 深证成指 创业板指 | | --- | --- | | 3353.07 | 10051.62 1994.82 | | -10.38 -0.31% | -75.58 -0.75% - - - 17.73 -0.88% | 高位股集体回调 今天上午， 高位股集体回调 ，王子新材、尚纬股份、国芳集团、永安药业、融发核电等 个股跌停 。另 外，科捷智能、博世科、保龄宝、欢乐家、久盛电气、中洲特材、哈焊华通等 多只高位股也大跌 。 上述个股主要来自三个板块：可控核聚变、大消费、无人驾驶。其中，可控核聚变板块上午大跌。 市场人士表示，可控核 ...

中国基金报记者安曼 端午节前最后一个交易日，美国关税政策反复，亚太市场早盘整体走低。 【导读】银行股逆市拉升，创新药板块批量涨停 消息落地后，银行股逆市拉升。 杭州银行、成都银行双双创下历史新高。 中信银行涨超3%，中小银行涨幅居前。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 601998 | 中信银行 | 7.92 | 0.24 | 3.13% | | 601077 | 渝农商行 | 7.28 | 0.17 | 2.39% | | 601528 | 瑞丰银行 | 5.62 | 0.12 | 2.18% | | 002958 | 青农商行 | 3.43 | 0.07 | 2.08% | | 600000 | 浦发银行 | 12.39 | 0.22 | 1.81% | | 603323 | 苏农银行 | 5.98 | 0.10 | 1.70% | | 002948 | 青岛银行 | 4.98 | 0.08 | 1.63% | | 601825 | 沪农商行 | 8.93 | 0.14 | 1.59% | | 601838 | ...

Group 1 - The A-shares and Hong Kong stocks collectively declined on May 30, while the Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index rose against the trend [1] - The Tianhong Innovative Drug ETF (517380) increased by 1.77%, ranking among the top fifteen ETFs in the market, with significant gains from constituent stocks such as Ruizhi Pharmaceutical and Yangguang Nuohuo [1] - The Tianhong Innovative Drug ETF has accumulated a rise of over 6.5% from May 6 to May 29 [1] Group 2 - The Biopharmaceutical ETF (159859) closely tracks the National Index of Biopharmaceuticals and is the largest product in its category, also offering connecting funds [2] - On May 29, the National Medical Products Administration issued approvals for 11 new drugs, with five coming from innovative companies on the Sci-Tech Innovation Board, covering various treatment areas [2] - The 2025 ASCO conference is expected to showcase significant data from domestic innovative drugs, with 71 original research results from Chinese pharmaceutical companies selected for presentation [2] Group 3 - CITIC Securities predicts a clear trend of performance and valuation recovery in the healthcare industry in the second half of 2025, with a focus on innovation-driven and internationalization strategies [3] - The optimization of centralized procurement policies is expected to positively impact market sentiment and lead to a recovery in the valuation of many sub-sectors in the pharmaceutical industry [3]

智通财经5月30日电，创新药概念股盘中持续走强，万邦德、康弘药业、千红制药、华森制药、哈三 联、联化科技、海南海药、华纳药厂、睿智医药等10余股涨停，舒泰神、科兴制药、冠昊生物等涨超 10%。 创新药概念股持续走高 万邦德等10余股涨停 ...

Group 1 - The core viewpoint of the news highlights the significant performance of the innovative drug sector, with the Tianhong Innovative Drug ETF (517380) showing a nearly 20% increase year-to-date as of May 29, 2023 [1] - The Tianhong Innovative Drug ETF, launched in 2021, tracks the "Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50" index, providing comprehensive coverage of the innovative drug industry across A-shares and Hong Kong stocks [1] - On May 29, the National Medical Products Administration approved 11 new drugs, with five being from innovative companies listed on the Sci-Tech Innovation Board, covering various therapeutic areas including oncology and autoimmune diseases [1] Group 2 - The upcoming 2025 ASCO Annual Meeting in Chicago is expected to showcase significant data from domestic innovative drug companies, with 71 original research results from Chinese pharmaceutical companies selected for presentation [2] - The innovative drug sector is anticipated to gain increased attention and positive market sentiment, with institutional holdings currently at low levels and the sector's valuation significantly below historical averages [2] - The total amount of outbound transactions for innovative drugs has reached $45.5 billion since the beginning of 2025, indicating a strong trend towards internationalization and potential for future growth [3] Group 3 - The Chinese innovative drug industry has transitioned from imitation to rapid following and now to original innovation, marking a significant evolution in its development [3] - Most domestic innovative drugs currently in the U.S. are in clinical stages, with future milestones expected to validate the growth and internationalization of Chinese innovative drugs [3]